Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up
Keywords
progression after second line ...
progression after second line chemotherapy prostate cancer
#1
JOURNAL ARTICLE
Takahiro Kirisawa, Eijiro Nakamura, Tomoya Okuno, Hiroki Hagimoto, Ayumu Matsuda, Yasuo Shinoda, Motokiyo Komiyama, Hiroyuki Fujimoto, Yoshiyuki Matsui
Intermittent docetaxel therapy (IDT) is rarely used nowadays as a treatment option for men with metastatic castration-resistant prostate cancer (mCRPC) because of the widespread availability of androgen receptor axis-targeted therapy, which is less toxic. Therefore, there is limited information available on whether IDT has a clinical benefit in the treatment of men with mCRPC. This report describes the case of a 66-year-old man with a diagnosis of cT2N1M0 prostate cancer who underwent neoadjuvant combined androgen blockade and whole-pelvis radiation therapy...
April 2024: International cancer conference journal
#2
JOURNAL ARTICLE
Yuto Tsubonuma, Keita Funakoshi, Tomohisa Takaba, Kazumasa Jyojima, Akinori Minato, Ikko Tomisaki, Kenichi Harada, Naohiro Fujimoto
Neuroendocrine prostate cancer (NEPC) is a histological variant of prostate cancer and is characterized by aggressiveness and poor clinical outcomes. NEPC usually develops as a mechanism of treatment resistance in patients receiving hormone therapy for advanced prostate cancer. NEPC is sensitive to primary platinum-based chemotherapy, and has a short response duration. Second-line therapy is required in many cases, but clinical data on subsequent treatment after progression to first-line chemotherapy is limited...
2024: Journal of UOEH
#3
JOURNAL ARTICLE
Yusuf Zeki Celen, Umut Elboga, Ertan Sahin, Tulay Kus, Merve Okuyan, Yusuf Burak Cayirli, Sakip Erturhan, Ufuk Cimen
OBJECTIVE: We aimed to evaluate the efficacy oflutetium-177-prostate-specific membrane antigen-617 (177 Lu-PSMA-617) with the luteinizing hormone releasing hormone (LHRH) analogues in the first or in the second-line setting formetastatic castration sensitive patients and metastatic castration resistance after progression with LHRH analogues. SUBJECTS AND METHODS: Sixteen consecutive patients with high volume metastatic prostate cancer undergone 177 Lu-PSMA-617 therapy who were refused chemotherapy and were unable to use new generation anti-androgen drugs because of unavailibility of reimbursement, were included in this retrospective study...
2023: Hellenic Journal of Nuclear Medicine
#4
JOURNAL ARTICLE
Mariaconsiglia Ferriero, Francesco Prata, Umberto Anceschi, Serena Astore, Alfredo Maria Bove, Aldo Brassetti, Fabio Calabrò, Silvia Chiellino, Cosimo De Nunzio, Gaetano Facchini, Elisena Franzese, Michela Izzo, Riccardo Mastroianni, Leonardo Misuraca, Richard Naspro, Rocco Papalia, Annalisa Pappalardo, Giorgia Tema, Gabriele Tuderti, Beatrice Turchi, Andrea Tubaro, Giuseppe Simone
Registrative trials recommended the use of upfront chemotherapy in high-volume metastatic prostate cancer. We reported survival outcomes of patients with high-volume mCRPC treated with ARTA in a chemo-naïve setting compared to patients treated with chemotherapy as first-line from a longitudinal real-life multicenter series. We retrospectively collected data on mCRPC patients treated at six centers. The dataset was queried for high-volume disease (defined as more than 6 bone lesions or bulky nodes ≥ 5 cm)...
September 29, 2023: Cancers
#5
JOURNAL ARTICLE
Daniel B Rosen, Anushka Ghosh, Andrzej Niemierko, Clair J Beard, Praful Ravi, Alok Tewari, Christopher Sweeney, Richard J Lee, Philip Saylor, Neil Martin, Jason A Efstathiou, Kent Mouw, Sophia C Kamran
BACKGROUND: Chemotherapy (CHT) or radiation therapy (RT) are first line treatments for clinical stage II testicular seminoma (CS-II). Historically, clinical stage I (CS-I) seminoma was also treated with CHT or RT, but in the past two decades practice has shifted towards active surveillance for CS-Iwith RT or CHT reserved for patients with progression to CS-II. Limited data exist on contemporary RT techniques and patient stratification, i.e. de novo (CS-II at orchiectomy) vs. relapsed (CS-II diagnosed during surveillance after orchiectomy for CS I)...
September 15, 2023: International Journal of Radiation Oncology, Biology, Physics
#6
JOURNAL ARTICLE
Tao Zhang, Vilmar Bandero, Claire Corcoran, Ismael Obaidi, Manuel Ruether, John O'Brien, Lorraine O'Driscoll, Neil Frankish, Helen Sheridan
Over the past decades, designing of privileged structures has emerged as a useful approach to the discovery and optimisation of novel biologically active molecules, and many have been successfully exploited across and within different target families. Examples include indole, quinolone, isoquinoline, benzofuran and chromone, etc. In the current study, we focus on synthesising a novel hybrid scaffold constituting naturally occurring benzophenone (14) and indanone (22) ring systems, leading to a general structure of 2-(diphenylmethylene)-2,3-dihydro-1H-inden-1-one (23)...
July 15, 2023: European Journal of Pharmaceutical Sciences
#7
JOURNAL ARTICLE
Qaid Ahmed Shagera, Ioannis Karfis, Spyridon Sideris, Thomas Guiot, Erwin Woff, Nieves Martinez-Chanza, Thierry Roumeguere, Thierry Gil, Patrick Flamen, Carlos Artigas
PURPOSE: The aim of this study was to evaluate the prognostic value of 68Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in metastatic castration-resistant prostate cancer patients receiving second-line chemotherapy with cabazitaxel. METHODS: All patients with metastatic castration-resistant prostate cancer who underwent a PSMA PET/CT within 8 weeks before initiating the cabazitaxel treatment were retrospectively evaluated. The whole-body PSMA total tumor volume (PSMA-TV) was measured for each patient...
June 29, 2023: Clinical Nuclear Medicine
#8
JOURNAL ARTICLE
Karin Holmsten, Johanna Eknert, Elisabeth Öfverholm, Dimitrios Papantoniou, Faith Jawdat, Ingrida Verbiéné, Anna Laurell, Elin Jänes, Johan Sandzén, Elzbieta Wojtyna-Dziedzic, Ida Lagstam, Karin Söderkvist, Fernanda Costa Svedman, Fredrik Liedberg, Martin Bruzelius, Ann-Sofie Fransson, Sofia Kjellström, Lise Hoej Omland, Helle Pappot, Anders Ullén
BACKGROUND: Immune checkpoint inhibitors (ICIs) have been established as a routine treatment in patients with metastatic urothelial cancer (mUC). However, there has been no standard of care after progression on ICIs. We investigated real-world treatment patterns and efficacy of chemotherapy (CHT) after pembrolizumab, in the era before introduction of maintenance avelumab and antibody-drug conjugates (ADC). PATIENTS AND METHODS: An observational, retrospective study was conducted at twelve Nordic centers...
May 17, 2023: Clinical Genitourinary Cancer
#9
JOURNAL ARTICLE
Tomas Januskevicius, Rasa Sabaliauskaite, Daiva Dabkeviciene, Ieva Vaicekauskaite, Ilona Kulikiene, Agne Sestokaite, Asta Vidrinskaite, Arnas Bakavicius, Feliksas Jankevicius, Albertas Ulys, Sonata Jarmalaite
(1) Background: DNA damage response (DDR) pathway gene mutations are detectable in a significant number of patients with metastatic castration-resistant prostate cancer (mCRPC). The study aimed at identification of germline and/or somatic DDR mutations in blood and urine samples from patients with mCRPC for correlation with responses to entire sequence of systemic treatment and survival outcomes. (2) Methods: DDR gene mutations were assessed prospectively in DNA samples from leukocytes and urine sediments from 149 mCRPC patients using five-gene panel targeted sequencing...
March 2, 2023: Biomedicines
#10
JOURNAL ARTICLE
Hideto Ueki, Tomoaki Terakawa, Takuto Hara, Junichiro Hirata, Naoe Jimbo, Yasuyoshi Okamura, Yukari Bando, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa
OBJECTIVE: This study retrospectively reviewed the clinical characteristics and treatment outcomes of patients with histologically diagnosed treatment-related pure small-cell neuroendocrine prostate cancer. METHODS: We retrospectively evaluated data for 13 patients with treatment-related neuroendocrine prostate cancer who were diagnosed between May 2015 and February 2022. Standardized systemic therapies of etoposide plus cisplatin (or carboplatin), amrubicin and nogitecan were selected as sequential treatments...
February 24, 2023: Japanese Journal of Clinical Oncology
#11
REVIEW
Shade' A Ahmed, Patricia Mendonca, Rashid Elhag, Karam F A Soliman
Cancer accounts for one in seven deaths worldwide and is the second leading cause of death in the United States, after heart disease. One of the standard cancer treatments is chemotherapy which sometimes can lead to chemoresistance and treatment failure. Therefore, there is a great need for novel therapeutic approaches to treat these patients. Novel natural products have exhibited anticancer effects that may be beneficial in treating many kinds of cancer, having fewer side effects, low toxicity, and affordability...
December 17, 2022: International Journal of Molecular Sciences
#12
JOURNAL ARTICLE
Mariaconsiglia Ferriero, Francesco Prata, Riccardo Mastroianni, Cosimo De Nunzio, Giorgia Tema, Gabriele Tuderti, Alfredo Maria Bove, Umberto Anceschi, Aldo Brassetti, Leonardo Misuraca, Silvana Giacinti, Fabio Calabrò, Salvatore Guaglianone, Andrea Tubaro, Rocco Papalia, Costantino Leonardo, Michele Gallucci, Giuseppe Simone
BACKGROUND: Available data on medical treatment of metastatic castration resistant prostate cancer (mCRPC) support the use of more than one therapy line to delay chemotherapy. We evaluate in a longitudinal real life multicenter cohort, the oncological outcome of mCRPC patients treated with Abiraterone Acetate (AA) and Enzalutamide (EZ) in a chemo-naïve setting, who received locoregional treatments for subsequent development of oligorecurrent disease. METHODS: We prospectively collected data on chemo-naïve mCRPC patients, who received either AA or EZ as first or second line treatment between Oct-2012 and Nov-2020 at 5 centers...
December 2, 2022: Prostate Cancer and Prostatic Diseases
#13
JOURNAL ARTICLE
Xiaojun Zhang
Prostate cancer (PC) is the most common malignancy of the male genitourinary system. For patients with advanced progressive PC, the treatment strategies include second-line endocrine therapy, chemotherapy, and immunotherapy. Such therapeutic techniques are either too expensive or too toxic for some patients, and traditional Chinese medicine (TCM) has become an alternative for its low cost and low toxicity. The application of Shi-pi-san and Gui-zhi-Fu-ling-wan in PC has never been reported. We report their application on a 71-year-old male patient, who was diagnosed with PC and was undergoing endocrine therapy...
September 2022: American Journal of Men's Health
#14
JOURNAL ARTICLE
Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Tanya Jindal, Vadim S Koshkin, Joseph J Park, Ajjai Alva, Mehmet A Bilen, Tyler F Stewart, Rana R McKay, Nishita Tripathi, Neeraj Agarwal, Naomi Vather-Wu, Yousef Zakharia, Rafael Morales-Barrera, Michael E Devitt, Alessio Cortellini, Claudia Angela Maria Fulgenzi, David J Pinato, Ariel Nelson, Christopher J Hoimes, Kavita Gupta, Benjamin A Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Fröbe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Eric Lu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson-Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Pedro Barata, Guru Sonpavde, Jonathan L Wright, Evan Y Yu, Robert Bruce Montgomery, Andrew C Hsieh, Petros Grivas, Ali Raza Khaki
BACKGROUND: Early progression on first-line (1L) platinum-based therapy or between therapy lines may be a surrogate of more aggressive disease and poor outcomes in advanced urothelial carcinoma (aUC), but its prognostic role regarding immune checkpoint inhibitor (ICI) response and survival is unclear. We hypothesized that shorter time until start of second-line (2L) ICI would be associated with worse outcomes in aUC. PATIENTS AND METHODS: We performed a retrospective multi-institution cohort study in patients with aUC treated with 1L platinum-based chemotherapy, who received 2L ICI...
August 19, 2022: Clinical Genitourinary Cancer
#15
JOURNAL ARTICLE
S Ay, Ö Efiloğlu, D Tataroğlu Özyükseler, Ö Dülgar, U Mutlu Günaydın, A Yıldırım, M Gümüş
OBJECTIVE: Prostate cancer (PCa) is the second most common solid tumor in men and the fifth leading cause of cancer-related death. In advanced stage, palliative treatments are used instead of curative therapies. Therefore, finding predictive indicators seems crucial. Patients with castration-resistant prostate cancer (CRPC) that received Dx chemotherapy have been retrospectively reviewed. The aim of this study was to investigate whether docetaxel (Dx)-free interval could have a predictive value for PCa and influence other sequential therapies...
June 30, 2022: Actas urologicas españolas
#16
JOURNAL ARTICLE
Zoé Neviere, Elodie Coquan, Pierre-Emmanuel Brachet, Emeline Meriaux, Isabelle Bonnet, Sophie Krieger, Laurent Castéra, Dominique Vaur, Flavie Boulouard, Alexandra Leconte, Justine Lequesne, Anais Lelaidier, Agathe Ricou, Florence Joly
(1) Background: In literature, approximately 20% of mCRPC present somatic DNA damage repair (DDR) gene mutations, and their relationship with response to standard therapies in mCRPC is not well understood. The objective was to evaluate outcomes of mCRPC patients treated with standard therapies according to somatic DDR status. (2) Methods: Eighty-three patients were recruited at Caen Cancer Center (France). Progression-free survival (PFS) after first-line treatment was analyzed according to somatic DDR mutation as primary endpoint...
April 15, 2022: Current Oncology
#17
RANDOMIZED CONTROLLED TRIAL
Giulia Baciarello, Remy Delva, Gwenaelle Gravis, Youssef Tazi, Philippe Beuzeboc, Marine Gross-Goupil, Emmanuelle Bompas, Florence Joly, Charlotte Greilsamer, Thierry Nguyen Tan Hon, Philippe Barthelemy, Stephane Culine, Jean Francois Berdah, Mathilde Deblock, Raffaele Ratta, Aude Flechon, Caroline Cheneau, Aline Maillard, Geraldine Martineau, Isabelle Borget, Karim Fizazi
BACKGROUND: The taxanes docetaxel and cabazitaxel prolong overall survival for men with metastatic castration-resistant prostate cancer (mCRPC), with cabazitaxel approved in the postdocetaxel setting only. Recent data suggest they have similar efficacy but a different safety profile in the first-line mCRPC setting. OBJECTIVE: To assess patient preference between docetaxel and cabazitaxel among men who received one or more doses of each taxane and did not experience progression after the first taxane...
March 2022: European Urology
#18
RANDOMIZED CONTROLLED TRIAL
Susanna Bianchi, Alessandra Mosca, Alberto Dalla Volta, Veronica Prati, Cinzia Ortega, Consuelo Buttigliero, Elena Fea, Paola Vanella, Francesca Valcamonico, Manuel Zamparini, Zuzana Sirotova, Isabella Chiappino, Orietta Dal Canton, Cristina Masini, Cosimo Sacco, Domenico Amoroso, Francesco Montagnani, Alessandro Comandone, Andrea R Bellissimo, Giovannino Ciccone, Susanne Baier, Alessandra Gennari, Marcello Tucci, Alfredo Berruti
BACKGROUND: This study was designed to demonstrate the non-inferiority (NI) in overall survival (OS) of suspension of androgen deprivation therapy (ADT) versus maintenance and intermittent versus continuous docetaxel administration in metastatic castration-resistant prostate cancer (mCRPC) patients. PATIENTS AND METHODS: mCRPC patients were randomised to first-line docetaxel with maintenance or suspension of ADT. Patients attaining a prostate-specific antigen (PSA) response after four chemotherapy cycles underwent second randomisation to receive continuous or intermittent docetaxel therapy...
September 2021: European Journal of Cancer
#19
MULTICENTER STUDY
Daniel H Kwon, Jonathan Chou, Steven M Yip, Melissa A Reimers, Li Zhang, Francis Wright, Mallika S Dhawan, Hala T Borno, Arpita Desai, Rahul R Aggarwal, Alexander W Wyatt, Eric J Small, Ajjai S Alva, Kim N Chi, Felix Y Feng, Vadim S Koshkin
BACKGROUND: DNA damage repair mutations (DDRm) are common in patients with metastatic castration-resistant prostate cancer (mCRPC). The optimal standard therapy for this population is not well described. METHODS: A multi-institutional, retrospective study of patients with mCRPC and DDRm was conducted. Patient data, including systemic therapies and responses, were collected. The decline in prostate-specific antigen ≥ 50% from baseline (PSA50) and overall survival (OS) from the treatment start were compared by mutation and treatment type...
June 15, 2021: Cancer
#20
JOURNAL ARTICLE
Danielle Meyrick, Marat Gallyamov, Shanthi Sabarimurugan, Nadia Falzone, Nat Lenzo
BACKGROUND: Lutetium-177 prostate-specific membrane antigen (177 Lu-PSMA) radioligand therapy is emerging as a promising treatment for metastatic castration-resistant prostate cancer refractory to established therapies. While there is an increasing body of survival and other data from retrospective analyses and prospective trials, there is no clear understanding of how best to predict therapy response and survival outcomes. OBJECTIVE: In this retrospective cohort analysis, we aimed to identify features that are associated with response to radioligand therapy and greater survival based on analysis of real-world data...
May 2021: Targeted Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
